Perifosine in renal cell carcinoma

Expert Opinion on Investigational Drugs

Volumn 22, Issue 2, 2013, Pages 285-291

  Srivastava, Neeharika ^a   Cho, Daniel C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Akt; Perifosine; PI3 kinase; Renal cancer

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERFERON; PAZOPANIB; PERIFOSINE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; CYTOPENIA; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GOUT; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; KIDNEY CARCINOMA; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; MYALGIA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR STRUCTURE; PHOSPHORYLCHOLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872184207     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.754422     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
2. Fyfe GA, Fisher RI, Rosenberg SA, et al. Long-Term response data for 255 patients with metastatic renal cell carcinoma treated with high-Dose recombinant interleukin-2 therapy. J Clin Oncol 1996;14(8):2410-11 (Pubitemid 26264899)
3. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 patients with metastatic melanoma or renal cell cancer using high-Dose bolus interleukin-2. JAMA 1994;271:907-13
4. Medical Research Council and Collaborators. Interferon-Alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet 1999;353(9146):14-17
5. Kenck C, Wilhelm M, Bugert P, et al. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 1996;179(2):157-61 (Pubitemid 26201583)
6. Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-Familial clear cell renal carcinoma. Hum Mol Genet 1994;3(12):2169-73
7. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-Alpha to the von Hippel-Lindau ubiquitylation complex by O2-Regulated prolyl hydroxylation. Science 2001;292(5516):468-72 (Pubitemid 32335942)
8. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1(8):822-6
9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34 (Pubitemid 46089673)
10. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178(5):1883-7 (Pubitemid 47538608)
11. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11 (Pubitemid 350296300)
12. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
13. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011;378(9807):1931-9
14. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81 (Pubitemid 46849157)
15. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
16. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as intial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 2012;30(Suppl):abstract 4501
17. Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2(11):1093-103
18. Smorenburg CH, Seynaeve C, Bontenbal M, et al. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anticancer Drugs 2000;11(10):825-8
19. Bendell JC, Nemunaitis J, Vukelja SJ, et al. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 2011;29(33):4394-400
20. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010;16(3):1033-41
21. Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007;5(7):433-7 (Pubitemid 351219696)
22. Leighl NB, Dent S, Clemons M, et al. A phase II study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat.2008;108(1):87-92 (Pubitemid 351623244)
23. Marsh Rde W, Rocha Lima CM, Levy DE, et al. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2007;30(1):26-31 (Pubitemid 46213821)
24. Bailey HH, Mahoney MR, Ettinger DS, et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 2006;107(10):2462-7 (Pubitemid 44748530)
25. Argiris A, Cohen E, Karrison T, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006;5(7):766-70 (Pubitemid 44775131)
26. Bendell JC, Ervin TJ, Senzer NN, et al. Results of the X-pECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol 2012;30(Suppl):abstract LBA3501
27. http://clinicaltrials.gov/ct2/show/NCT01002248
28. Poradosu E, Lemmon MA, Keleti D. Perifosine selectively inhibits binding of Akt PH domain to PtdINS (3,4)P2 [abstract 1645]. Proceedings of the American Association for Cancer Research Annual Meeting; 2007
29. Fu L, Kim YA, Wang X, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 2009;69(23):8967-76
30. Crul M, Rosing H, de Klerk GJ, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002;38(12):1615-21 (Pubitemid 34876501)
31. Unger C, Berdel W, Hanauske AR, et al. First-Time-In-Man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer 2010;46(5):920-5
32. Hennessey BT, Lu Y, Poradosu E, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007;13(24):7421-31
33. Hilgard P, Klenner T, Stekar J, et al. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 1997;33(3):442-6 (Pubitemid 27168072)
34. Vink SR, Schellens JH, van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 2005;23(4):279-86 (Pubitemid 40980350)
35. Stephenson J, Schreeder J, Waples J, et al. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI). J Clin Oncol 2007;18(Suppl): Abstract 15622
36. Cho DC, Hutson TE, Samlowski W, et al. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-Targeted therapy. Cancer 2012; In press
37. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : Final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
38. Chiarini F, Del Sole M, Mongiorgi S, et al. The novel Akt inhibitor, perifosine, induces caspase-Dependent apoptosis and downregulates P-glycoprotein expression in multidrug-Resistant human T-Acute leukemia cells by a JNK-Dependent mechanism. Leukemia 2008;22(6):1106-16 (Pubitemid 351833776)
39. Kumar A, Fillmore HL, Kadian R, et al. The alkylphospholipid perifosine induces apoptosis and p21-Mediated cell cycle arrest in medulloblastoma. Mol Cancer Res 2009;7(11):1813-21
40. Elrod HA, Lin YD, Yue P, et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 2007;6(7):2029-38 (Pubitemid 47052493)
41. David E, Sinha R, Chen J, et al. Perifosine synergistically enhances TRAIL-Induced myeloma cell apoptosis via up-Regulation of death receptors. Clin Cancer Res 2008;14(16):5090-8
42. Tazzari PL, Tabellini G, Ricci F, et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells. Cancer Res 2008;68(22):9394-403
43. Celeghini C, Voltan R, Rimondi E, et al. Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines. Invest New Drugs 2011;29(2):392-5
44. Wang FZ, Fei HR, Li XQ, et al. Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells. Mol Cell Biochem 2012;368(1-2):1-8
45. Guo JP, Coppola D, Cheng JQ. IKBKE activates Akt independent of phosphatidylinositol 3-kinase/PDK1mTORC2 and PH domain to sustain malignant transformation. J Biol Chem 2011;286(43):37389-98
46. Cirstea D, Hideshima T, Rodig S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-Rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010;9(4):963-75
47. Holland WS, Tepper CG, et al. Evaluating rational non-cross-Resistant combination therapy in advanced clear cell renal cell carcinoma: Combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol 2012;69(1):185-94
48. Pitter KL, Galba'n CJ, Galba'n S, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven murine glioblastoma. PLoS One 2011;6(1):e14545
49. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24 (Pubitemid 46089672)